PRESTIGE BIOPHARMA LIMITED

Highlights Prestige BioPharma Limited

Equities

A950210

KR8702070002

End-of-day quote Korea S.E. Other stock markets 23:00:00 04/06/2024 BST			5-day change	1st Jan Change
8,530 ^KRW	-1.95%		+6.62%	-10.02%

2023	Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	CI
2023	Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	21/03/23	CI
Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	09/03/23	CI
Prestige Biopharma Submits Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar	14/10/22	CI
Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the Us, Europe, Canada, Mena, Brazil, Mexico, South Africa, Cis and the Sea Countries	26/07/22	CI
US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510	27/06/22	CI
Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine	29/03/22	CI
The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue®), Published in JAMA Oncology	11/03/22	CI
Prestige BioPharma Limited Announces Preclinical Data of Pancreatic Cancer Treatment, PBP1510, Present in ESMO TAT 2022	08/03/22	CI
Prestige BioPharma Limited Commences Construction of Innovative Discovery Center in Busan, Korea	19/12/21	CI
Prestige BioPharma and Dr. Reddy’s Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia	09/12/21	CI
Prestige BioPharma : Institutional Shareholders, Appreciate its High Growth Potential and Invest with a Long-term View	02/08/21	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW